03/14/2017Pharma Industry News Update: 14 March 2017

What does it take to be a successful digital leader – e.g., Chief Digital Officer (CDO) – in a big pharmaceutical company? Consultants at McKinsey & Company try to answer this question by interviewing executives at ten companies. Are they talking to the right people?
How to Succeed as Chief Digital Officer in Pharma

From www.mckinsey.com

The life-sciences industry is embracing digital to unlock innovation. McKinsey spoke to CDOs and their equivalents at ten pharma companies to understand how they focus their efforts.

These conversations suggest three imperatives for digital efforts.

Learn about the three imperatives here…

Spoiler Alert: This article appears to be talking about CDOs with customer-facing exposure (e.g., experts who “Creating intuitive interfaces so executives, physicians, or patients can use – and help improve – the tools will be mostly a design and marketing challenge.”). I don’t think I know any such CDOs employed by an actual Big Pharmaceutical company (most CDOs quoted in this article are CEOs or CDOs of small companies aligned with the pharma industry and not any of the big pharma companies).

Further Reading:

Digital Health Technology is Taking Off in Clinical Trials

From insights.samsung.com

In a new survey (of 166 biopharma and life sciences industry researchers, executives and technology/software professionals) on how digital health devices and data impact clinical trials, digital health technology vendor Validic reported:

  1. Sixty percent of respondents said they have used digital health technology to conduct clinical trials.
  2. Ninety-seven percent of respondents said they will increase their use of digital technologies in clinical trials in the next five years.

More findings here…

Further Reading:

Trump Chooses Scott Gottlieb to Head FDA; Pharma Breathes Sigh of Relief

From www.cnbc.com

President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday.

If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.

Gottlieb is well known on Capitol Hill, where he has testified multiple times on hot-button health issues, including complex drug pricing matters, and is viewed favorably by drug companies and pharmaceutical investors. He sits on the boards of several small drug and biotech companies and is an adviser to GlaxoSmithKline Plc.

“Thank God it’s Gottlieb,” Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note. “We view this as a favorable development for the sector.”

More here…

PG: Gottlieb received the most votes (27%) in my survey. Strangely, Jim O’Neill received 0%! See the results here. I’ve heard that Many Former #FDA Employees Take the “Revolving Door” & End Up Working for #Pharma (here) and that #Pharma Nearly Decimates FDA’s CDER Division by “Poaching” Employees (here), but I haven’t heard of a case of the “double-dutch” or FDA-Pharma-FDA revolving door, where a former FDA employee is hired by pharma who then later becomes FDA commissioner.